newsfilter
← Latest News
Business Wire·

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

FDA Type C Meeting and Nonclinical Study Advance Strategy to Transition LT-100 from 15 Injections to One Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced